Prostate Cancer No More Likely to Develop After Testosterone Therapy
The incidence of prostate cancer (PCa) during long-term testosterone replacement treatment was equivalent to that expected in the general population, according to a study of 1,365 men aged 28-87 years (mean 55 years) with symptomatic androgen deficiency. All patients received testosterone treatment and had been monitored for up to 20 years, during which 14 new PCa […]
Continue reading →